N/A N=26 Bioequivalence Study of Letrozole 2.5 mg Tablets
Healthy
Primary: Letrozole : AUC0-tz — 2074.71; 2094.63 ng•hr/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=56 Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.
Healthy
Primary: Maximum Observed Plasma Concentration of Hyoscine Butylbromide (Cmax) — 91; 80 picogram (pg)/millilitre (mL)
Phase 1 N=60 Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules
Hepatitis C
Primary: Area Under the Curve of the Analyte From Time 0 to the Last Quantifiable Data Point (AUC0-tz) — 17297.157; 17216.514 ng·h/mL
N/A N=28 Bioequivalence Study for Mejoral 500 Product
Pain
Primary: Area Under the Curve From Time Zero to Last Sampling Time [AUC(0-t)] — 15.212; 14.698 hours*microgram/millilitre (h*μg/mL)
Phase 1 N=72 Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Healthy
Primary: Baseline Corrected Maximum Observed Plasma Concentration (Cmax[Adj]) of Levothyroxine Sodium — 67.258; 60.552 Nanogram per milliliter (ng/mL)
Phase 1 N=36 Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State
Type 2 Diabetes Mellitus
Primary: Saxagliptin Maximum Observed Concentrations (Cmax) — 26.2; 25.5 ng/mL — p=0.4950
Phase 1 N=70 Relative Bioavailability of 2 Oral Formulations of Nintedanib
Healthy
Primary: AUC0-tz — 300; 310; 306 ng*h/mL — p=<0.0001
Phase 1 N=12 Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)
Type 2 Diabetes Mellitus
Primary: Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin) — 8.38; 8.78 μmol*hr/L
Phase 1 N=64 A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 1270.92; 1320.24…
Phase 1 N=64 A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2275.77; 2166.70…
Phase 1 N=34 Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.
Prostatic Hyperplasia
Primary: Cmax — 21700; 20520 pg/mL
Phase 1 N=18 Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Tepotinib — 15348; 16523 Hours*nanogram per milliliter…
Phase 1 N=40 Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate
Epilepsy
Primary: Cmax - Maximum Plasma Concentration — 6461; 13183; 6547; 12988 ng/ml
Phase 1 N=28 SPD544 High Strength Bioequivalence Study
ADHD
Primary: Area Under the Steady-state Plasma Concentration-time Curve (AUC 0-t) for Methylphenidate Hydrochloride (MPH) Using Two Different Formulations (Equasym XL and Metadate…
Phase 1 N=14 Fenofibrate Bioequivalence Study (0767-031)
Dyslipidemia
Primary: Area Under the Curve (AUC(0 to Infinity)) of Fenofibric Acid — 116; 121 μg·hr/mL
Phase 4 N=24 Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate
Bacterial Infection
Primary: Maximum Plasma Concentration (Cmax) of Doxycycline — 2.526; 2.442 ug/mL
Phase 1 N=180 Bioequivalence of Two Different Capsule Types of Dabigatran
Healthy
Primary: Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran — 1147.64; 908.48 ng*hr/mL
Phase 1 N=32 Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions
Bioequivalence
Primary: Concentration Maximum (Cmax) — 0.9092; 0.8711 ng/ml
Phase 4 N=20 Triomune Bioequivalence With Innovators
HIV/AIDS
Primary: Area Under the Concentration-Time Curve(AUC) — 3.6; 3.4; 85.8; 79.2 hour*milligram/liter
Phase 1 N=32 Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets
Healthy
Primary: Area Under Curve From 0 to tz Hours (AUC0-tz) of Metformin — 7219.03; 7057.52 ng·h/mL
Phase 4 N=35 Lamotrigine Bioequivalence
Epilepsy
Primary: AUC — 101346; 101393 ng*hr/ml
Phase 1 N=50 Nicotine Lozenge Bioequivalence Study
Smoking Cessation
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t [AUC(0-t)] — 18.84; 20.71; 34.71; 33.68 nanogram (ng).hour (hr)/millilitre (mL)
Phase 4 N=76 Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet
Hypercholesterolemia
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity) — 18.3206; 19.2583 ng•hr/mL
Phase 4 N=76 Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet
Hypercholesterolemia
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity) — 168.1355; 176.1731 ng*hr/mL
Phase 1 N=21 Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg
Healthy Adult Male
Primary: Maximum (Peak) Plasma Concentration (Cmax) of Brexpiprazole — 23.31; 24.24; 23.75 ng/mL
Phase 3 N=999 Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma
Asthma
Primary: Baseline-adjusted Area Under the Serial FEV1-time Curve Calculated From Time Zero to 12 Hours (AUC0-12h) on Day 1 of Treatment — 4.03; 3.96 liters x hours
Phase 1 N=32 Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t)…
Phase 1 N=43 Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.
Healthy Adults
Primary: Mean Plasma Concentration (AUC) of Cyclobenzaprine — 70066.90; 64711.53 pg*h/mL
Phase 1 N=18 Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 270.31; 248.46 ng / ml
Phase 1 N=24 Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)
Hereditary Tyrosinemia, Type I
Primary: Maximum Observed Plasma Concentration (Cmax) — 1277.77; 1272.34; 1339.79 ng/mL